drugset / Trial / NCT00531440
This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
RandomizedParallel-groupOpen-labelPrevention
Summary
This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.
Timeline
- Start
- 2001-11
- Primary completion
- 2005-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 1.5 mg | — |
| Subject | Everolimus | Small molecule | 3 mg | — |
Indications
No indication recorded.